Payment overview · 2025
General Payments
$1,347.73
71 reported records · 18 companies
Healthcare provider profile · identity verified
Michael Keith Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · HUNTSVILLE, AL · NPI 1174574172
Verified facts
What the public records show
CMS Open Payments records show Michael Keith Johnson, MD received $1,347.73 in general payments during 2025 across 71 reported records.
Novo Nordisk Inc accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 427 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $219.59 | 16.3% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $177.60 | 13.2% | 9 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $159.14 | 11.8% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $146.10 | 10.8% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $144.91 | 10.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $83.45 | 6.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $77.56 | 5.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $73.38 | 5.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.14 | 4.0% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $46.39 | 3.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.99 | 2.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.57 | 2.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.17 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.41 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.97 | 1.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.84 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.19 | 1.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.33 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,347.73 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $223.66 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $201.57 | 16 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $159.14 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $144.91 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $122.23 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $114.15 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $83.45 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $73.38 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.14 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $46.39 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.56 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.57 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 90 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 147 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 165 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 28 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
165 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
53 | 20 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
427 | 71 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 840 | 280 |
| Amlodipine Besylate | Amlodipine Besylate | 614 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 531 | 105 |
| Eliquis | Apixaban | 427 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 393 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 275 | 80 |
| Gabapentin | Gabapentin | 268 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 263 | 68 |
| Omeprazole | Omeprazole | 256 | 87 |
| Losartan Potassium | Losartan Potassium | 244 | 65 |
| Lisinopril | Lisinopril | 218 | 66 |
| Metformin Hcl | Metformin Hcl | 216 | 57 |
| Potassium Chloride | Potassium Chloride | 210 | 56 |
| Furosemide | Furosemide | 208 | 54 |
| Carvedilol | Carvedilol | 207 | 62 |
| Donepezil Hcl | Donepezil Hcl | 170 | 31 |
| Ozempic | Semaglutide | 165 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 152 | 36 |
| Xarelto | Rivaroxaban | 151 | 19 |
| Jardiance | Empagliflozin | 147 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 146 | 65 |
| Allopurinol | Allopurinol | 140 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 37 |
| Memantine Hcl | Memantine Hcl | 137 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 125 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 26 |
| Myrbetriq | Mirabegron | 113 | 15 |
| Levetiracetam | Levetiracetam | 111 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 29 |
| Mirtazapine | Mirtazapine | 110 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 44 |
| Montelukast Sodium | Montelukast Sodium | 108 | 33 |
| Warfarin Sodium | Warfarin Sodium | 105 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 104 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 30 |
| Trazodone Hcl | Trazodone Hcl | 93 | 39 |
| Simvastatin | Simvastatin | 91 | 21 |
| Farxiga | Dapagliflozin Propanediol | 90 | 24 |
| Methocarbamol | Methocarbamol | 87 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 30 |
| Finasteride | Finasteride | 82 | 19 |
| Januvia | Sitagliptin Phosphate | 77 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 77 | 72 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 30 |
| Sucralfate | Sucralfate | 72 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 19 |
| Olanzapine | Olanzapine | 67 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 15 |
| Divalproex Sodium | Divalproex Sodium | 64 | 16 |
| Ondansetron Odt | Ondansetron | 64 | 24 |
| Clonazepam | Clonazepam | 62 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 62 | suppressed |
| Spironolactone | Spironolactone | 59 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 58 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 23 |
| Megestrol Acetate | Megestrol Acetate | 56 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 14 |
| Risperidone | Risperidone | 53 | suppressed |
| Rybelsus | Semaglutide | 53 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 20 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 50 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 47 | 26 |
| Latanoprost | Latanoprost | 46 | suppressed |
| Primidone | Primidone | 46 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 46 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 17 |
| Famotidine | Famotidine | 43 | 18 |
| Linzess | Linaclotide | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Telmisartan | Telmisartan | 42 | 20 |
| Buspirone Hcl | Buspirone Hcl | 41 | 13 |
| Metformin Hcl Er | Metformin Hcl | 41 | 18 |
| Azelastine Hcl | Azelastine Hcl | 40 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 19 |
| Rexulti | Brexpiprazole | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 22 |
| Topiramate | Topiramate | 38 | suppressed |
| Kerendia | Finerenone | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | 13 |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Ezetimibe | Ezetimibe | 33 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Lubiprostone | Lubiprostone | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | 14 |
| Prednisone | Prednisone | 32 | 15 |
| Vascepa | Icosapent Ethyl | 32 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 23 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 13 |
| Santyl | Collagenase Clostridium Hist. | 30 | 13 |
| Torsemide | Torsemide | 30 | 14 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 20 |
| Gemtesa | Vibegron | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 18 |
| Alendronate Sodium | Alendronate Sodium | 28 | 12 |
| Alprazolam | Alprazolam | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 23 |
| Tramadol Hcl | Tramadol Hcl | 26 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 19 |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 18 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Briviact | Brivaracetam | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | 11 |
| Colchicine | Colchicine | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Nystop | Nystatin | 15 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 13 |
| Steglatro | Ertugliflozin Pidolate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,347.73 · 71 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, VOWST | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error